BUY Dr. Lal Path Labs Ltd. — Arun Kumar Mantri
byArun Kumar MantriHorizon: Intraday25 Sept 2026, 9:31 am ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Dr. Lal Path Labs Ltd. approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. SN Genelab will become a subsidiary.
NSE · Outcome of Board Meeting·24 Sept · today
Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance linked earn out. This acquisition aims to strengt
BSE · Company Update·24 Sept · today
Dr. Lal PathLabs Ltd announced board approval for the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores plus performance-linked earn out. SN Genelab will become a subsidi
BSE · Others·24 Sept · today
1 advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·25 Sept · today
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.